New Medications

Survodutide: The Dual GLP-1/Glucagon Drug That Could Change Obesity Treatment

GLP-1 Companion · 6 min read

Quick answer

Survodutide targets two receptors simultaneously — GLP-1 and glucagon — and early trial data shows weight loss that may rival or exceed current treatments. Here is what we know so far.

A new class of obesity drugs is moving beyond GLP-1 alone. Survodutide (development code BI 456906), developed by Boehringer Ingelheim in partnership with Zealand Pharma, simultaneously activates two different metabolic receptors. Early clinical trial data suggests it could deliver substantial weight loss — and the mechanism is fundamentally different from drugs like semaglutide (Wegovy) or tirzepatide (Zepbound).

What Is Survodutide?

Survodutide is a dual glucagon and GLP-1 receptor agonist (GcgR/GLP-1RA). That means it binds to and activates both the glucagon receptor and the GLP-1 receptor, whereas drugs like semaglutide activate only the GLP-1 receptor.

This dual mechanism is the key innovation. GLP-1 receptor activation reduces appetite and slows gastric emptying — the same pathway exploited by Ozempic and Wegovy. The added glucagon receptor activation increases energy expenditure: the body burns more calories even at rest, and the liver processes fat more aggressively.

Developer: Boehringer Ingelheim (lead) and Zealand Pharma (co-developer)
Development code: BI 456906
Mechanism: Dual GLP-1 receptor / glucagon receptor agonist
Format: Weekly subcutaneous injection (similar to Ozempic/Wegovy)
Current stage: Phase 3 clinical trials (as of 2026)
Target conditions: Obesity and metabolic dysfunction-associated steatohepatitis (MASH)

Why Target the Glucagon Receptor?

Glucagon is often described as the opposite of insulin — it raises blood sugar and signals the liver to release stored energy. That sounds counterintuitive for a weight loss drug. But glucagon receptor activation has a useful side effect: it strongly increases energy expenditure and promotes fat breakdown in the liver.

The challenge with pure glucagon agonists is that they raise blood glucose levels, which is dangerous. The solution is pairing glucagon activation with GLP-1 receptor activation, which lowers blood sugar and suppresses appetite. The two mechanisms counterbalance each other metabolically while combining their fat-burning effects.

This is the same logic behind tirzepatide (Zepbound/Mounjaro), which pairs GLP-1 with GIP receptor activation. Survodutide takes a different pairing — GLP-1 with glucagon — and may have an especially strong effect on liver fat, making it a candidate for MASH treatment as well as obesity.

What the Clinical Trial Data Shows

The most closely watched results come from a Phase 2 trial published in The Lancet in 2024. The trial tested survodutide across four doses in adults with obesity or overweight (with at least one weight-related condition) over 46 weeks.

Phase 2 Weight Loss Results

Highest dose group (4.8 mg): approximately 18.7% average body weight reduction
Second highest (3.6 mg): approximately 15.8% average body weight reduction
Placebo group: approximately 2.8% average body weight reduction
Duration: 46 weeks of treatment

These are Phase 2 results with a smaller sample size than Phase 3 trials, so they come with significant uncertainty. Phase 3 results — which will involve thousands of participants and longer treatment windows — will be the definitive test.

MASH (Liver Disease) Data

Survodutide has also shown strong signals in metabolic dysfunction-associated steatohepatitis (MASH), formerly called NASH — a progressive liver disease driven by fat accumulation. In a Phase 2 MASH trial, survodutide showed meaningful improvements in liver inflammation and fibrosis markers, and Boehringer Ingelheim advanced it to Phase 3 trials for this indication separately from obesity.

Survodutide vs. Semaglutide vs. Tirzepatide

Comparing across different trial designs and populations is imprecise, but the Phase 2 numbers put survodutide in a similar weight loss range as tirzepatide and potentially above semaglutide:

Semaglutide 2.4 mg (Wegovy, STEP 1 trial): ~14.9% average weight loss at 68 weeks
Tirzepatide 15 mg (Zepbound, SURMOUNT-1 trial): ~20.9% average weight loss at 72 weeks
Survodutide 4.8 mg (Phase 2, 46 weeks): ~18.7% average weight loss
CagriSema (Phase 3): ~22.7% average weight loss at 68 weeks

These numbers are not directly comparable — different trials, different populations, different durations. Survodutide's Phase 2 data involves fewer participants than approved drugs' Phase 3 data, and Phase 3 results will likely look different. But the Phase 2 signal is strong enough that Boehringer Ingelheim is investing heavily in Phase 3 development.

Side Effects and Tolerability

The Phase 2 trial side effect profile looked broadly similar to other GLP-1 drugs, though with some differences reflecting the glucagon component:

Nausea, vomiting, and diarrhea — common GLP-1 class effects, seen in higher frequency at higher doses
Gastrointestinal side effects were most common during dose escalation
Injection site reactions (mild)
No significant hypoglycemia in people without diabetes — expected given the GLP-1 counterbalance to glucagon's blood-sugar-raising effect
Discontinuation rates due to side effects were higher at the highest dose in Phase 2 (around 12-15%)

The glucagon component raises a question about bone health: sustained glucagon receptor activation can affect calcium and bone metabolism. This is being monitored in Phase 3 trials.

Development Timeline

Boehringer Ingelheim initiated Phase 3 trials for survodutide in obesity in 2024 under the SYNCHRONIZE program. These large-scale trials will run for 72+ weeks and include tens of thousands of participants.

2021–2022: Phase 1 trials establishing safety and dosing in humans
2022–2024: Phase 2 trials in obesity and MASH — positive results in both
2024: Phase 3 trials initiated (SYNCHRONIZE program for obesity, separate MASH program)
2026: Phase 3 trials ongoing; no FDA submission yet
Estimated FDA submission: 2027–2028 if Phase 3 results are positive

If Phase 3 results confirm the Phase 2 signal, survodutide could reach pharmacies sometime in the late 2020s — adding a third major option to what would then be an increasingly crowded obesity drug market.

How Does It Fit Into the Landscape?

The obesity drug pipeline now includes multiple candidates with different mechanisms, and each has a potential niche. Semaglutide (Wegovy) remains the established standard. Tirzepatide (Zepbound) has largely matched or exceeded it on weight loss in head-to-head comparisons. CagriSema (cagrilintide + semaglutide) is being developed by Novo Nordisk as the next step beyond Wegovy.

Survodutide's distinguishing features are its dual GLP-1/glucagon mechanism and its particularly strong signal for liver disease. If approved, it could be positioned both as an obesity drug and as the first major treatment for MASH — a disease that affects an estimated 6–8% of adults globally and currently has very limited treatment options.

The glucagon component gives survodutide a potentially unique effect on liver fat that purely GLP-1-based drugs may not match. This could make it the preferred choice for patients with obesity and concurrent liver disease.

Can I Get Survodutide Now?

No. Survodutide is an investigational drug that is not FDA-approved and not available by prescription outside of clinical trials. There is no legitimate way to obtain it outside of an approved clinical study.

If you are interested in participating in a survodutide clinical trial, you can search ClinicalTrials.gov for active studies. Eligibility criteria vary, and participation involves close medical monitoring.

The Bottom Line

Survodutide is one of the most closely watched drugs in the obesity pipeline. Its dual GLP-1/glucagon mechanism is theoretically compelling, its Phase 2 weight loss data is competitive with currently approved drugs, and its liver disease signal gives it a potential indication beyond obesity. Phase 3 results — expected in 2027 — will determine whether it delivers on that early promise.

For now, the best available approved treatments remain semaglutide (Wegovy/Ozempic) and tirzepatide (Zepbound/Mounjaro), both of which are proven in large Phase 3 trials. Anyone interested in starting GLP-1 treatment should discuss their options with a healthcare provider rather than waiting for drugs that are still in development.